文献速递前列腺癌

局部高危前列腺癌的临床与生物学特征:促黄体生成素释放激素激动剂联合或不联合醋酸阿比特龙加泼尼松的随机术前研究结果

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
PubMed 文献 · Eur Urol · 2019-06-06

这项单中心随机试验在65例局部高危前列腺癌患者中比较术前醋酸阿比特龙加泼尼松联合促黄体生成素释放激素激动剂与单用促黄体生成素释放激素激动剂后行根治性前列腺切除术的疗效。联合组肿瘤体积指标显著更低,肿瘤上皮体积较低与≥4年随访时生化无复发生存改善相关,未观察到新的安全性信号。

要点

  • 联合组肿瘤体积指标显著低于单药组,器官局限性癌无显著差异。
  • 肿瘤上皮体积较低与≥4年随访生化无复发生存改善相关。
  • 糖皮质激素受体过表达与联合组持续肿瘤相关,核雄激素受体剪接变异体与两组持续肿瘤相关。

核心结论

  • 首次研究术前醋酸阿比特龙加泼尼松联合促黄体生成素释放激素激动剂与单用促黄体生成素释放激素激动剂在局部高危前列腺癌中的作用,联合组肿瘤体积指标显著缩小且与生化复发负相关,糖皮质激素受体在雄激素生物合成抑制耐药中的潜在作用需进一步研究。

研究设计与样本

  • 单中心随机试验,65例局部高危前列腺癌患者接受术前醋酸阿比特龙加泼尼松联合促黄体生成素释放激素激动剂或单用促黄体生成素释放激素激动剂后行根治性前列腺切除术。

主要发现

  • 器官局限性癌无显著差异(p=0.27)。
  • 联合组肿瘤体积指标显著更低(p≤0.001)。
  • 肿瘤上皮体积较低与≥4年随访生化无复发生存改善相关(p=0.0014)。
  • 联合组肿瘤增殖和雄激素信号表达低于单药组。
  • 多变量分析中糖皮质激素受体过表达与联合组持续肿瘤相关(p=0.018),核雄激素受体剪接变异体与两组持续肿瘤相关;未观察到新的安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Optimal therapeutic strategy remains an unmet need in localised high-risk prostate cancer (LHRPC). Androgen biosynthesis inhibition in the preoperative setting may improve outcomes. In this single-centre randomised trial, we looked at therapy outcomes of preoperative treatment with abiraterone acetate+prednisone (AAP)+luteinising hormone-releasing hormone agonist (LHRHa) or LHRHa alone followed by radical prostatectomy in 65 men. We did not see a significant difference of organ-confined carcinoma (p=0.27). However, tumour volume measures were significantly lower for AAP+LHRHa treatment (p≤0.001). Of note, lower tumour epithelium volume correlated with improved biochemical recurrence-free survival at ≥4-yr follow-up (p=0.0014). Tumours pretreated with AAP+LHRHa had lower proliferation and androgen signalling expression than LHRHa. On multivariate analysis, glucocorticoid receptor (GR) overexpression correlated with persistent tumours in AAP+LHRHa (p=0.018). The presence of nuclear androgen receptor splice variant (nARV7) correlated with persistent tumours in both arms. No new safety signals were observed. This is the first study investigating the role of preoperative AAP+LHRHa versus LHRHa alone in LHRPC. We report significant cytoreduction by tumour volume measures inversely correlating with biochemical relapse. Validation of these proposed tumour volume measures is planned. A potential role of GR in resistance to androgen biosynthesis inhibition warrants further study. PATIENT SUMMARY: This is the first study of abiraterone acetate plus leuprolide versus leuprolide alone in high-risk localised prostate cancer followed by prostatectomy. Patients in the combination arm had a significantly smaller tumour size.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Efstathiou E, Davis JW, Pisters L, et al. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol. 2019. PMID: 31176622. doi:10.1016/j.eururo.2019.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。